[HTML][HTML] Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS …
…, J Xie, JC Curtin, N Haddish-Berhane… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)
exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …
exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …
Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin
To build a multiscale mechanism based pharmacokinetic–pharmacodynamic (PK/PD)
model for antibody drug conjugates (ADCs), using brentuximab-vedotin as an example, for …
model for antibody drug conjugates (ADCs), using brentuximab-vedotin as an example, for …
Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate …
…, K Atkinson, N Haddish-Berhane… - Journal of medicinal …, 2012 - ACS Publications
Glucokinase is a key regulator of glucose homeostasis, and small molecule allosteric
activators of this enzyme represent a promising opportunity for the treatment of type 2 diabetes. …
activators of this enzyme represent a promising opportunity for the treatment of type 2 diabetes. …
JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).
…, K Bae, RE Knoblauch, J Curtin, N Haddish-Berhane… - 2019 - ascopubs.org
9009 Background: JNJ-372 binds EGFR and cMet to block ligand binding, promote receptor
degradation, and trigger antibody-dependent cellular cytotoxicity in models of EGFR-…
degradation, and trigger antibody-dependent cellular cytotoxicity in models of EGFR-…
Antibody–drug conjugates: an emerging modality for the treatment of cancer
…, DK Shah, N Haddish‐Berhane… - Annals of the New …, 2014 - Wiley Online Library
… Shah and Haddish-Berhane emphasized objectives (1) to build and validate a multi-scale
mechanistic model for ADCs that can integrate in vitro biomeasures and preclinical PK/PD …
mechanistic model for ADCs that can integrate in vitro biomeasures and preclinical PK/PD …
[HTML][HTML] A translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-cadherin …
CD3 bispecific antibody constructs recruit cytolytic T cells to kill tumor cells, offering a potent
approach to treat cancer. T cell activation is driven by the formation of a trimolecular …
approach to treat cancer. T cell activation is driven by the formation of a trimolecular …
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach
N Haddish-Berhane, DK Shah, D Ma, M Leal… - … of pharmacokinetics and …, 2013 - Springer
Objectives of the present investigation were: (1) to compare three literature reported tumor
growth inhibition (TGI) pharmacodynamic (PD) models and propose an optimal new model …
growth inhibition (TGI) pharmacodynamic (PD) models and propose an optimal new model …
Preclinical to clinical translation of antibody-drug conjugates using PK/PD modeling: a retrospective analysis of inotuzumab ozogamicin
… and clearance of inotuzumab ozogamicin and its released payload N-Ac-γ-calicheamicin
DMH, (2… Tumor growth and inhibition is described using the Haddish-Berhane model (12), with …
DMH, (2… Tumor growth and inhibition is described using the Haddish-Berhane model (12), with …
Designing glucokinase activators with reduced hypoglycemia risk: discovery of N, N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl) benzofuran-4-yloxy) …
…, T D'Aquila, DR Derksen, N Haddish-Berhane… - …, 2011 - pubs.rsc.org
Glucokinase is a key regulator of glucose homeostasis and small molecule activators of this
enzyme represent a promising opportunity for the treatment of Type 2 diabetes. Several …
enzyme represent a promising opportunity for the treatment of Type 2 diabetes. Several …
1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced …
…, JR Infante, J Xie, N Haddish-Berhane… - Annals of …, 2020 - annalsofoncology.org
Background In preclinical studies, the combination of amivantamab (EGFR-MET bispecific
antibody) with lazertinib demonstrates synergistic inhibition of tumor growth. We present the …
antibody) with lazertinib demonstrates synergistic inhibition of tumor growth. We present the …